Hepatocellular Carcinoma CRISPR Knockout Cell Models for Drug Discovery

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 75–85% of cases. According to the World Health Organization (WHO) Global Cancer Observatory (GLOBOCAN 2022), liver cancer is the sixth most frequently diagnosed cancer worldwide and the third leading cause of cancer-related death, with an estimated 866,000 new cases and 759,000 deaths annually. The highest incidence rates are observed in Eastern Asia and Sub-Saharan Africa, largely driven by chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, as well as aflatoxin exposure. In Western countries, non-alcoholic steatohepatitis (NASH) and metabolic syndrome are emerging as major risk factors.

The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports that the 5-year relative survival rate for localized HCC is approximately 36%, but drops to 14% for regional disease and 3% for distant metastatic disease. This stark prognosis underscores the urgent need for better preclinical models to identify novel therapeutic targets and overcome drug resistance.

HCC is an ideal disease for mechanistic studies due to its well-characterized molecular subtypes (e.g., proliferative vs. non-proliferative), the availability of large public genomic datasets (TCGA, COSMIC, cBioPortal), and the presence of recurrent, actionable mutations in key pathways. Open questions include the role of tumor heterogeneity, the interplay between immune microenvironment and genetics, and the mechanisms of resistance to sorafenib and lenvatinib. Gene-edited cell models provide a controlled system to dissect these questions.

HCC development involves the progressive accumulation of genetic and epigenetic alterations. Key carcinogenic pathways include:

1. Telomere dysfunction and chromosomal instability: Shortened telomeres lead to breakage-fusion-bridge cycles, promoting genomic rearrangements.

2. Oxidative stress and DNA damage: Chronic inflammation from viral hepatitis or NASH generates reactive oxygen species (ROS) that cause DNA damage.

3. Epigenetic silencing: Hypermethylation of tumor suppressor gene promoters (e.g., CDKN2A, RASSF1A) contributes to clonal expansion.

4. Activation of oncogenic signaling: Mutations in CTNNB1, TP53, and TERT promoter drive uncontrolled proliferation.

Data from The Cancer Genome Atlas (TCGA) and COSMIC (Catalogue of Somatic Mutations in Cancer) reveal the following recurrent alterations in HCC:

Several signaling networks are frequently deregulated in HCC:

• • Wnt/beta-catenin pathway: Activating mutations in CTNNB1 or inactivating mutations in AXIN1 lead to nuclear accumulation of beta-catenin and transcription of pro-proliferative genes (MYC, CCND1).
• • MAPK/ERK pathway: Overexpression of growth factors (FGF, HGF) or mutations in RAS/RAF (less common in HCC than other cancers) can activate this pathway.
• • PI3K/AKT/mTOR pathway: PTEN loss or PIK3CA mutations (rare) lead to increased AKT signaling, promoting cell survival and growth.
• • p53 pathway: TP53 mutations impair DNA damage response, apoptosis, and senescence.
• • JAK/STAT pathway: Chronic inflammation drives STAT3 activation, contributing to tumor progression.
• • Key nodes include: beta-catenin, MYC, CCND1, AKT, STAT3, and p53.

Commonly used HCC cell lines and their key mutations are listed below. Organoids derived from patient tumors retain genetic heterogeneity and three-dimensional architecture, offering advantages for drug testing and personalized medicine.

Animal models are essential for studying HCC in a physiological context:

• • Patient-derived xenografts (PDX): Tumor fragments from patients are implanted into immunodeficient mice. They preserve tumor heterogeneity and are used for drug efficacy studies.
• • Genetically engineered mouse models (GEMM): Conditional knock-in of mutant CTNNB1 combined with TP53 deletion (e.g., Alb-Cre; Ctnnb1(ex3); Trp53(fl/fl)) recapitulates human HCC.
• • Chemically induced models: Diethylnitrosamine (DEN) administration in mice induces HCC with mutations in Hras and Braf.
• • Hydrodynamic tail vein injection: Delivery of transposon-based vectors (e.g., sleeping beauty) carrying oncogenes (MYC, AKT) and shRNAs against TP53 allows rapid tumor formation.

CRISPR/Cas9 technology enables the creation of isogenic cell lines that differ only in a specific genetic alteration, providing a clean system to study gene function. Examples include:

• • TP53 knockout in Huh-7 or HepG2 cells: Used to study p53 loss-of-function effects on proliferation, apoptosis, and genomic instability.
• • CTNNB1 G34V or S45del knock-in in TP53 wild-type cells: Models constitutive Wnt activation.
• • TERT promoter C228T knock-in: Recapitulates telomerase reactivation.
• • KRAS G12D knock-in: Although rare in HCC, this model is used to study MAPK pathway addiction.

Commercially available, sequence-verified CRISPR knockout and knock-in cell lines accelerate research by eliminating the time-consuming process of guide RNA design, transfection, and clonal selection. These models are validated by Sanger sequencing and functional assays, ensuring reproducibility.

Gene-edited cell lines are powerful tools for functional genomics. For example:

• • TP53 knockout in HepG2 cells demonstrated that p53 loss enhances cell proliferation and resistance to DNA-damaging agents (e.g., doxorubicin).
• • CTNNB1 knockout in Huh-7 cells reduced beta-catenin transcriptional activity and decreased expression of target genes (MYC, CCND1), confirming its role in proliferation.
• • ARID1A knockout in SNU-449 cells showed that loss of this chromatin remodeler alters gene expression profiles and increases sensitivity to EZH2 inhibitors.

Isogenic pairs (wild-type vs. knockout/knock-in) are ideal for drug screening:

• • Sorafenib resistance: TP53 knockout cells show reduced sensitivity to sorafenib, suggesting that p53 status influences response.
• • Wnt pathway inhibitors: CTNNB1 mutant cells are more sensitive to tankyrase inhibitors (e.g., XAV939) compared to wild-type cells.
• • Combination therapies: Isogenic lines can identify synthetic lethal interactions, such as the vulnerability of ARID1A-deficient cells to ATR inhibitors.

CRISPR-based screens in HCC cell lines can identify biomarkers and therapeutic targets:

• • Genome-wide CRISPR knockout screens in HepG2 cells identified genes whose loss confers resistance to sorafenib, revealing potential resistance mechanisms.
• • Synthetic lethality screens: TP53-deficient HCC cells are more dependent on WEE1 kinase, making WEE1 inhibitors a potential targeted therapy.
• • CRISPR activation (CRISPRa) screens can identify genes that, when overexpressed, drive resistance to lenvatinib.

The following databases provide essential genomic, transcriptomic, and functional data for HCC research: